Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alder Biopharma (ALDR)

Alder Biopharma (ALDR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 968,646
  • Shares Outstanding, K 83,504
  • Annual Sales, $ 0 K
  • Annual Income, $ -296,430 K
  • 60-Month Beta 2.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.99
  • Number of Estimates 5
  • High Estimate -0.68
  • Low Estimate -1.37
  • Prior Year -1.04
  • Growth Rate Est. (year over year) +4.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.57 +6.29%
on 05/29/19
12.53 -10.34%
on 06/18/19
+0.17 (+1.58%)
since 05/24/19
3-Month
10.40 +8.03%
on 05/20/19
14.39 -21.92%
on 04/03/19
-1.72 (-13.24%)
since 03/22/19
52-Week
9.44 +19.01%
on 12/24/18
20.87 -46.16%
on 08/08/18
-5.56 (-33.13%)
since 06/22/18

Most Recent Stories

More News
Relatively Good Performance Detected in Shares of Alder Biopharmac in the Biotechnology Industry (ALDR , TGTX , SGMO , NTRA , KPTI )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

SGMO : 9.58 (-3.72%)
TGTX : 6.93 (-4.41%)
ALDR : 11.17 (-3.71%)
Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors

Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a Phase 3-stage biopharmaceutical company developing STS101, (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today...

ALDR : 11.17 (-3.71%)
Alder BioPharmaceuticals(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee...

ALDR : 11.17 (-3.71%)
Alder BioPharmaceuticals(R) to Present at Two Upcoming May Investor Conferences

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management...

ALDR : 11.17 (-3.71%)
Alder BioPharmaceuticals(R) Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention

- Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate nearly 60% of patients reported very much or much improvement in most bothersome symptoms and in overall migraine status...

ALDR : 11.17 (-3.71%)
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up

Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.

JNJ : 143.06 (+0.68%)
ALDR : 11.17 (-3.71%)
EDIT : 21.79 (-4.56%)
GERN : 1.52 (+2.70%)
Alder BioPharmaceuticals(R) Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials

Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new efficacy data highlighting...

ALDR : 11.17 (-3.71%)
Alder BioPharmaceuticals(R) Reports First Quarter 2019 Financial and Operating Results

- FDA sets eptinezumab PDUFA date of February 21, 2020; launch expected in first quarter of 2020 -

ALDR : 11.17 (-3.71%)
Alder BioPharmaceuticals(R) to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results

Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its first...

ALDR : 11.17 (-3.71%)
Alder BioPharmaceuticals(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee...

ALDR : 11.17 (-3.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ALDR with:

Business Summary

Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and...

See More

Key Turning Points

2nd Resistance Point 11.95
1st Resistance Point 11.78
Last Price 11.17
1st Support Level 11.33
2nd Support Level 11.05

See More

52-Week High 20.87
Fibonacci 61.8% 16.50
Fibonacci 50% 15.15
Fibonacci 38.2% 13.81
Last Price 11.17
52-Week Low 9.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar